Progress in understanding the genetics of impaired hearing

Article

Our knowledge of the genetic causes of deafness is advancing rapidly, raising hopes for better diagnosis and more effective treatment in the near future.

Recent Videos
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Related Content
Nirsevimab shows strong real-world effectiveness against RSV in infants | Image credit: © Peter Hansen - stock.adobe.com.

Nirsevimab shows strong real-world effectiveness against RSV in infants

Morgan Ebert, Managing Editor
May 1st 2025
Article

Nirsevimab significantly reduces RSV-related hospitalisations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Full recap from the 2025 Pediatric Academic Societies meeting | Image Credit: © SCStock - © SCStock - stock.adobe.com.

Full recap from the 2025 Pediatric Academic Societies meeting

Joshua Fitch, Senior Editor
May 1st 2025
Article

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Elamipretide to treat Barth syndrome sees FDA target action delay | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Elamipretide to treat Barth syndrome sees FDA target action delay

Joshua Fitch, Senior Editor
April 30th 2025
Article

Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."

FDA approves nipocalimab-aahu to treat generalized myasthenia gravis | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves nipocalimab-aahu to treat generalized myasthenia gravis

Joshua Fitch, Senior Editor
April 30th 2025
Article

The human FcRn-blocking monoclonal antibody is indicated for gMG patients aged 12 years and older.

© 2025 MJH Life Sciences

All rights reserved.